Source - RNS
RNS Number : 3708M
Cyprotex PLC
13 October 2016
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

 

Cyprotex PLC

("Cyprotex" or "the Company")

Rule 2.9 Announcement - Relevant Securities in Issue

 

In accordance with Rule 2.9 of the Takeover Code, Cyprotex PLC, (AIM: CRX), confirms that it has the following securities in issue:

 

·      22,509,042 Ordinary Shares of 1 pence each in issue at the close of business on 12 October 2016 and the Ordinary Shares in the Company are admitted to trading on AIM under the UK ISIN code GB00BP25RZ14; and

 

·      4,584,645 of unsecured Convertible Loan Notes due in 30 September 2018 (the "Convertible Notes"). The Convertible Notes are convertible into Ordinary Shares in Cyprotex at a price of 60 pence per share. The Convertible Notes are admitted to the Official List of the Cayman Islands Stock Exchange under the International Securities Identification Number GB00BQ1XZQ04.

 

 

 

For further information:

 

Cyprotex PLC

Tel: +44 (0) 1625 505 100

Dr Anthony Baxter, Chief Executive Officer

John Dootson, Chief Financial Officer

Mark Warburton, Chief Operating Officer and Legal Counsel

[email protected]

www.cyprotex.com



N+1 Singer (Nomad, Broker & Rule 3 Adviser to Cyprotex)

Tel: +44 (0)20 7496 3000

Shaun Dobson

Jen Boorer

 

[email protected]

[email protected]

www.n1singer.com

Brown Gibbons Lang & Company

(Financial Adviser to Cyprotex)

Tel: +1 312 658 4774

 

John Riddle

J. Kyle Brown

 

[email protected]

[email protected]

Notes to Editors

About Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX).  It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US.  The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RTTGGGRUUUPQGGP

Related Charts

Cyprotex (CRX)

0.00p (0.00%)
delayed 18:15PM